Market Focus Target hospitals and cancer centers with Subsys and Dronabinol SG Capsule for breakthrough cancer pain and chemotherapy-induced nausea and vomiting, leveraging the unique sublingual delivery and specialized CNS formulations to expand adoption in oncology supportive care.

Expansion Opportunities Identify distribution partnerships and contract manufacturing arrangements to scale access in mid to large pharma networks, given the current revenue tier and the potential to broaden the portfolio with related CNS and pain management products.

Regulatory & Compliance Assess potential reentry or settlement strategies around past regulatory scrutiny to restore trust with payers and providers, highlighting robust clinical data and manufacturing controls as differentiators for payer negotiations.

Payer & Reimbursement Develop value dossiers emphasizing cost of care reductions and improved patient outcomes for Subsys and Dronabinol SG Capsule to engage insurers and managed care organizations, aiming for favorable formulary placements.

Clinical & Education Propose clinically drivenKOL engagement and speaker bureau partnerships focusing on education around breakthrough cancer pain management and CINV protocols, aiming to expand prescribing pathways and physician adoption.